-
2
-
-
79954493924
-
Committee opinion no 477 the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer
-
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice.
-
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee opinion no. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117: 742-6.
-
(2011)
Obstet Gynecol
, vol.117
, pp. 742-746
-
-
-
3
-
-
84863078516
-
Vignette-based study of ovarian cancer screening: Do U.S physicians report adhering to evidence-based recommendations?
-
Baldwin LM, Trivers KF, Matthews B, Andrilla CH, Miller JW, Berry DL, et al. Vignette-based study of ovarian cancer screening: Do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med 2012;156: 182-94.
-
(2012)
Ann Intern Med
, vol.156
, pp. 182-194
-
-
Baldwin, L.M.1
Trivers, K.F.2
Matthews, B.3
Andrilla, C.H.4
Miller, J.W.5
Berry, D.L.6
-
4
-
-
55349134617
-
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
-
DOI 10.1373/clinchem.2008.105601
-
Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79. (Pubitemid 352777353)
-
(2008)
Clinical Chemistry
, vol.54
, Issue.12
-
-
Sturgeon, C.M.1
Duffy, M.J.2
Stenman, U.-H.3
Lilja, H.4
Brunner, N.5
Chan, D.W.6
Babaian, R.7
Bast Jr., R.C.8
Dowell, B.9
Esteva, F.J.10
Haglund, C.11
Harbeck, N.12
Hayes, D.F.13
Holten-Andersen, M.14
Klee, G.G.15
Lamerz, R.16
Looijenga, L.H.17
Molina, R.18
Nielsen, H.J.19
Rittenhouse, H.20
Semjonow, A.21
Shih, I.-M.22
Sibley, P.23
Soletormos, G.24
Stephan, C.25
Sokoll, L.26
Hoffman, B.R.27
Diamandis, E.P.28
more..
-
5
-
-
79958036419
-
Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
-
for the PLCO Project Team.
-
Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al., for the PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305: 2295-303.
-
(2011)
JAMA
, vol.305
, pp. 2295-2303
-
-
Buys, S.S.1
Partridge, E.2
Black, A.3
Johnson, C.C.4
Lamerato, L.5
Isaacs, C.6
-
6
-
-
77957571905
-
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24
-
Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010;42: 874-9.
-
(2010)
Nat Genet
, vol.42
, pp. 874-879
-
-
Goode, E.L.1
Chenevix-Trench, G.2
Song, H.3
Ramus, S.J.4
Notaridou, M.5
Lawrenson, K.6
-
7
-
-
69349102630
-
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2
-
Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry- Maharaj A, Wozniak E, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009; 41: 996-1000.
-
(2009)
Nat Genet
, vol.41
, pp. 996-1000
-
-
Song, H.1
Ramus, S.J.2
Tyrer, J.3
Bolton, K.L.4
Gentry- Maharaj, A.5
Wozniak, E.6
-
8
-
-
77957584092
-
Common variants at 19p13 are associated with susceptibility to ovarian cancer
-
Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010;42: 880-4.
-
(2010)
Nat Genet
, vol.42
, pp. 880-884
-
-
Bolton, K.L.1
Tyrer, J.2
Song, H.3
Ramus, S.J.4
Notaridou, M.5
Jones, C.6
-
9
-
-
84875707717
-
GWAS metaanalysis and replication identifies three new susceptibility loci for ovarian cancer
-
70e1-2
-
Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS metaanalysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013;45:362-70, 70e1-2.
-
(2013)
Nat Genet
, vol.45
, pp. 362-370
-
-
Pharoah, P.D.1
Tsai, Y.Y.2
Ramus, S.J.3
Phelan, C.M.4
Goode, E.L.5
Lawrenson, K.6
-
10
-
-
84858853451
-
Role of common genetic variants in ovarian cancer susceptibility and outcome: Progress to date from the Ovarian Cancer Association Consortium (OCAC)
-
Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med 2012;271: 366-78.
-
(2012)
J Intern Med
, vol.271
, pp. 366-378
-
-
Bolton, K.L.1
Ganda, C.2
Berchuck, A.3
Pharaoh, P.D.4
Gayther, S.A.5
-
11
-
-
34748848707
-
Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients
-
DOI 10.1016/j.ygyno.2007.07.024, PII S0090825807004957
-
Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, et al. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 2007;107:S223-9. (Pubitemid 47487477)
-
(2007)
Gynecologic Oncology
, vol.107
, Issue.1 SUPPL.
-
-
Saldivar, J.S.1
Lu, K.H.2
Liang, D.3
Gu, J.4
Huang, M.5
Vlastos, A.-T.6
Follen, M.7
Wu, X.8
-
12
-
-
80053591338
-
Genetic variants in TGF- pathway are associated with ovarian cancer risk
-
Yin J, Lu K, Lin J, Wu L, Hildebrandt MA, Chang DW, et al. Genetic variants in TGF- pathway are associated with ovarian cancer risk. PLoS One 2011;6:e25559.
-
(2011)
PLoS One
, vol.6
-
-
Yin, J.1
Lu, K.2
Lin, J.3
Wu, L.4
Hildebrandt, M.A.5
Chang, D.W.6
-
13
-
-
78649977193
-
Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response
-
Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, et al. Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res 2010;70: 9765-76.
-
(2010)
Cancer Res
, vol.70
, pp. 9765-9776
-
-
Liang, D.1
Meyer, L.2
Chang, D.W.3
Lin, J.4
Pu, X.5
Ye, Y.6
-
14
-
-
84859415553
-
Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer
-
Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012;18: 1855-62.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1855-1862
-
-
Brooks, A.N.1
Kilgour, E.2
Smith, P.D.3
-
15
-
-
0030746972
-
A secreted FGF-binding protein can serve as the angiogenic switch in human cancer
-
DOI 10.1038/nm1097-1137
-
Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ, Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 1997;3: 1137-40. (Pubitemid 27444457)
-
(1997)
Nature Medicine
, vol.3
, Issue.10
, pp. 1137-1140
-
-
Czubayko, F.1
Liaudet-Coopman, E.D.E.2
Aigner, A.3
Tuveson, A.T.4
Berchem, G.J.5
Wellstein, A.6
-
16
-
-
75149170979
-
Fibroblast growth factor signalling: From development to cancer
-
Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10: 116-29.
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 116-129
-
-
Turner, N.1
Grose, R.2
-
17
-
-
79959713140
-
Fibroblast growth factors and their receptors in cancer
-
Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011;437: 199-213.
-
(2011)
Biochem J
, vol.437
, pp. 199-213
-
-
Wesche, J.1
Haglund, K.2
Haugsten, E.M.3
-
18
-
-
77949277517
-
FGFR2 mutations are rare across histologic subtypes of ovarian cancer
-
Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, Pollock PM. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol 2010;117: 125-9.
-
(2010)
Gynecol Oncol
, vol.117
, pp. 125-129
-
-
Byron, S.A.1
Gartside, M.G.2
Wellens, C.L.3
Goodfellow, P.J.4
Birrer, M.J.5
Campbell, I.G.6
Pollock, P.M.7
-
19
-
-
84874030601
-
Identification of FGFR4 as a potential therapeutic target for advancedstage, high-grade serous ovarian cancer
-
Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, et al. Identification of FGFR4 as a potential therapeutic target for advancedstage, high-grade serous ovarian cancer. Clin Cancer Res 2013;19: 809-20.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 809-820
-
-
Zaid, T.M.1
Yeung, T.L.2
Thompson, M.S.3
Leung, C.S.4
Harding, T.5
Co, N.N.6
-
20
-
-
84866981538
-
Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors
-
Madsen CV, Steffensen KD, Olsen DA, Waldstrøm M, Søgaard CH, Brandslund I, Jakobsen A. Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors. Anticancer Res 2012;32: 3817-25.
-
(2012)
Anticancer Res
, vol.32
, pp. 3817-3825
-
-
Madsen, C.V.1
Steffensen, K.D.2
Olsen, D.A.3
Waldstrøm, M.4
Søgaard, C.H.5
Brandslund, I.6
Jakobsen, A.7
-
21
-
-
33644855779
-
From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer
-
DOI 10.1002/ijc.21521
-
Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer 2006;118: 1750-8. (Pubitemid 43376439)
-
(2006)
International Journal of Cancer
, vol.118
, Issue.7
, pp. 1750-1758
-
-
Le Page, C.1
Ouellet, V.2
Madore, J.3
Hudson, T.J.4
Tonin, P.N.5
Provencher, D.M.6
Mes-Masson, A.-M.7
-
22
-
-
34250200790
-
Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas
-
DOI 10.1200/JCO.2006.09.0795
-
Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, et al. Whole genome oligonucleotidebased array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. Clin Oncol 2007;25: 2281-7. (Pubitemid 46954656)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.16
, pp. 2281-2287
-
-
Birrer, M.J.1
Johnson, M.E.2
Hao, K.3
Wong, K.-K.4
Park, D.-C.5
Bell, A.6
Welch, W.R.7
Berkowitz, R.S.8
Mok, S.C.9
-
23
-
-
84867395354
-
Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
-
Smith G, Ng MT, Shepherd L, Herrington CS, Gourley C, Ferguson MJ, Wolf CR. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. Br J Cancer 2012;107: 1327-36.
-
(2012)
Br J Cancer
, vol.107
, pp. 1327-1336
-
-
Smith, G.1
Ng, M.T.2
Shepherd, L.3
Herrington, C.S.4
Gourley, C.5
Ferguson, M.J.6
Wolf, C.R.7
-
24
-
-
76749136307
-
Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype
-
Murphy T, Darby S, Mathers ME, Gnanapragasam VJ. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol 2010;220: 452-60.
-
(2010)
J Pathol
, vol.220
, pp. 452-460
-
-
Murphy, T.1
Darby, S.2
Mathers, M.E.3
Gnanapragasam, V.J.4
-
25
-
-
40549124915
-
Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous β-catenin
-
DOI 10.1002/humu.20653
-
Abdel-Rahman WM, Kalinina J, Shoman S, Eissa S, Ollikainen M, Elomaa O, et al. Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous -catenin. Hum Mutat 2008;29: 390-7. (Pubitemid 351364941)
-
(2008)
Human Mutation
, vol.29
, Issue.3
, pp. 390-397
-
-
Abdel-Rahman, W.M.1
Kalinina, J.2
Shoman, S.3
Eissa, S.4
Ollikainen, M.5
Elomaa, O.6
Eliseenkova, A.V.7
Butzow, R.8
Mohammadi, M.9
Peltomaki, P.10
-
26
-
-
79952818552
-
Overview of anti-angiogenic agents in development for ovarian cancer
-
Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011;121: 230-8.
-
(2011)
Gynecol Oncol
, vol.121
, pp. 230-238
-
-
Burger, R.A.1
-
27
-
-
80053493427
-
Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis
-
Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011;17: 6130-9.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6130-6139
-
-
Lieu, C.1
Heymach, J.2
Overman, M.3
Tran, H.4
Kopetz, S.5
-
28
-
-
67249140681
-
Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: Results from the Ovarian Cancer Association Consortium
-
Johnatty SE, Beesley J, Chen X, Spurdle AB, Defazio A, Webb PM, et al. Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the Ovarian Cancer Association Consortium. Twin Res Hum Genet 2009;12: 269-75.
-
(2009)
Twin Res Hum Genet
, vol.12
, pp. 269-275
-
-
Johnatty, S.E.1
Beesley, J.2
Chen, X.3
Spurdle, A.B.4
Defazio, A.5
Webb, P.M.6
-
31
-
-
77957232748
-
Genevar: A database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies
-
Yang TP, Beazley C, Montgomery SB, Dimas AS, Gutierrez-Arcelus M, Stranger BE, et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 2010;26: 2474-6.
-
(2010)
Bioinformatics
, vol.26
, pp. 2474-2476
-
-
Yang, T.P.1
Beazley, C.2
Montgomery, S.B.3
Dimas, A.S.4
Gutierrez-Arcelus, M.5
Stranger, B.E.6
-
32
-
-
36648999834
-
FGF signaling in prostate tumorigenesis-new insights into epithelial-stromal interactions
-
DOI 10.1016/j.ccr.2007.11.021, PII S1535610807003418
-
Abate-Shen C, Shen MM. FGF signaling in prostate tumorigenesis - new insights into epithelialstromal interactions. Cancer Cell 2007;12: 495-7. (Pubitemid 350199077)
-
(2007)
Cancer Cell
, vol.12
, Issue.6
, pp. 495-497
-
-
Abate-Shen, C.1
Shen, M.M.2
-
33
-
-
36649036989
-
Enhanced Paracrine FGF10 Expression Promotes Formation of Multifocal Prostate Adenocarcinoma and an Increase in Epithelial Androgen Receptor
-
DOI 10.1016/j.ccr.2007.11.002, PII S1535610807003339
-
Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, Witte ON. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 2007;12: 572-85. (Pubitemid 350199069)
-
(2007)
Cancer Cell
, vol.12
, Issue.6
, pp. 572-585
-
-
Memarzadeh, S.1
Xin, L.2
Mulholland, D.J.3
Mansukhani, A.4
Wu, H.5
Teitell, M.A.6
Witte, O.N.7
-
34
-
-
61649100307
-
The FGF family: Biology, pathophysiology and therapy
-
Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8: 235-53.
-
(2009)
Nat Rev Drug Discov
, vol.8
, pp. 235-253
-
-
Beenken, A.1
Mohammadi, M.2
-
35
-
-
0035855624
-
Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer
-
DOI 10.1038/sj.onc.1204755
-
Steele IA, Edmondson RJ, Bulmer JN, Bolger BS, Leung HY, Davies BR. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 2001;20: 5878-87. (Pubitemid 32937957)
-
(2001)
Oncogene
, vol.20
, Issue.41
, pp. 5878-5887
-
-
Steele, I.A.1
Edmondson, R.J.2
Bulmer, J.N.3
Bolger, B.S.4
Leung, H.Y.5
Davies, B.R.6
-
36
-
-
77957116888
-
Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer
-
Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C, et al. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther 2010;10: 495-504.
-
(2010)
Cancer Biol Ther
, vol.10
, pp. 495-504
-
-
Cole, C.1
Lau, S.2
Backen, A.3
Clamp, A.4
Rushton, G.5
Dive, C.6
-
37
-
-
20444496900
-
Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium
-
DOI 10.1158/1078-0432.CCR-04-1386
-
Whitworth MK, Backen AC, Clamp AR, Wilson G, McVey R, Friedl A, et al. Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res 2005;11: 4282-8. (Pubitemid 40825614)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.12
, pp. 4282-4288
-
-
Whitworth, M.K.1
Backen, A.C.2
Clamp, A.R.3
Wilson, G.4
Mc Vey, R.5
Friedl, A.6
Rapraeger, A.C.7
David, G.8
McGown, A.9
Slade, R.J.10
Gallagher, J.T.11
Jayson, G.C.12
-
38
-
-
30944460953
-
Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines
-
DOI 10.1080/08977190500361697, PII X1174636870X4201
-
Steele IA, Edmondson RJ, Leung HY, Davies BR. Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines. Growth Factors 2006;24: 45-53. (Pubitemid 43108775)
-
(2006)
Growth Factors
, vol.24
, Issue.1
, pp. 45-53
-
-
Steele, I.A.1
Edmondson, R.J.2
Leung, H.Y.3
Davies, B.R.4
-
39
-
-
84872294755
-
Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells
-
Byron SA, Loch DC, Pollock PM. Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. Int J Gynecol Cancer 2012;22: 1517-26.
-
(2012)
Int J Gynecol Cancer
, vol.22
, pp. 1517-1526
-
-
Byron, S.A.1
Loch, D.C.2
Pollock, P.M.3
-
40
-
-
84860596557
-
Patterns of cis regulatory variation in diverse human populations
-
Stranger BE, Montgomery SB, Dimas AS, Parts L, Stegle O, Ingle CE, et al. Patterns of cis regulatory variation in diverse human populations. PLoS Genet. 2012;8:e1002639.
-
(2012)
PLoS Genet.
, vol.8
-
-
Stranger, B.E.1
Montgomery, S.B.2
Dimas, A.S.3
Parts, L.4
Stegle, O.5
Ingle, C.E.6
|